Trump to Nominate Overton as FDA Commissioner
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Heidi Overton, deputy director of domestic policy at the White House, is expected to be nominated by President Trump as the next FDA commissioner, according to STAT
- Overton has led health policy at the White House since the start of Trump's second term, working closely with HHS, and has at times frustrated leaders of the Make America Healthy Again movement
- If nominated, Overton would need to face scrutiny from a U.S. Senate panel before assuming the commissioner role
- A personalized mRNA cancer vaccine from Merck and Moderna slowed melanoma recurrence and spread in a late-stage clinical trial, though detailed data was not immediately released
- If the melanoma results hold up, approval would boost Moderna's mRNA platform, which STAT notes has become a political lightning rod
Why it matters: An Overton-led FDA would install a White House insider who has reportedly clashed with MAHA movement leaders atop drug regulation, while a Merck/Moderna melanoma vaccine readout — if confirmed — would validate an mRNA platform that has drawn political opposition.
Ask SkimNews
